Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

CTP-543 is generally safe for treating alopecia areata.

This article reviews triamcinolone acetonide as an intramuscular long-acting steroid therapy for dermatologic disorders but reports no new clinical results.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This paper reviews the use of tacrolimus for various conditions, noting its effectiveness in treating certain skin disorders but highlighting that some findings remain anecdotal due to limited case numbers.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Among patients treated at Thomas Jefferson University, this study found that adding cryotherapy to intralesional triamcinolone acetonide (IL TAC) was more effective at reducing keloid size compared to IL TAC alone, although both treatments similarly eased pruritus and pain.

This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.

This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.

This study found that tildacerfont treatment in males with congenital adrenal hyperplasia reduced androgen levels and improved markers of testicular function, suggesting potential benefits for male reproductive health.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study found that switching patients with alopecia areata unresponsive to topical clobetasol 17 propionate 0.05% to anthralin treatment led to improved treatment success.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.

This study reported that the combination of tacrolimus, clobetasol, and minoxidil improved hair measurements and stabilized inflammation in primary cicatricial alopecia patients, with most tolerating the treatment well.

This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

In this report, two young patients with corticosteroid-refractory alopecia totalis experienced safety and efficacy from oral tacrolimus.

This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.

This review reports that topical tacrolimus appears to be a safe and effective short-term treatment for inflammatory skin disorders, though further study is needed to assess long-term safety and efficacy.

This study found that clobetasol propionate 0.05% was significantly more effective in stimulating hair re-growth in alopecia areata patients compared to topical tacrolimus 0.1%, with an excellent response observed in 74.3% of the clobetasol group versus 40% in the tacrolimus group.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

In this study, topical tacrolimus 0.03% cream showed good to excellent response in treating alopecia areata in 70% of participants, with no cutaneous or systemic side effects observed.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.